WO2024180206 - PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
National phase entry:
Publication Number
WO/2024/180206
Publication Date
06.09.2024
International Application No.
PCT/EP2024/055317
International Filing Date
01.03.2024
Title **
[English]
PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
[French]
DÉRIVÉS PYRIDAZINYL AMINO UTILISÉS EN TANT QU'INHIBITEURS D'ALK5
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
PIZZIRANI, Daniela
RONCHI, Paolo
PALA, Daniele
RESCIGNO, Donatella
Priority Data
23159706.3
02.03.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2185 | |
| EPO | Filing, Examination, Granting | 9404 | |
| Japan | Filing, Examination, Granting | 2055 | |
| South Korea | Filing, Examination, Granting | 1780 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
20,764
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention generally relates to compounds (I) inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.[French]
La présente invention concerne de manière générale des composés (I) inhibant le récepteur de facteur de croissance transformant β (TGF β) de type I (ALK5) (ci-après, inhibiteurs d'ALK5), des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles, par exemple, dans le traitement de maladies, troubles ou états nombreux associés à la voie de signalisation ALK5.